Reliability and validity of the Portuguese version of the Generalized Anxiety Disorder (GAD-7) scale

Tiago V Sousa, Vânia Viveiros, Maria V Chai, Filipe L Vicente, Gustavo Jesus, Maria J Carnot, Ana C Gordo, Pedro L Ferreira, Tiago V Sousa, Vânia Viveiros, Maria V Chai, Filipe L Vicente, Gustavo Jesus, Maria J Carnot, Ana C Gordo, Pedro L Ferreira

Abstract

Background: Generalized anxiety disorder has a strong impact on health-related quality of life. For this reason, it seems relevant to develop strategies allowing early diagnoses in order to promote appropriate treatments. The objective of this study was to culturally adapt and validate the GAD-7 for the Portuguese patients with generalized anxiety disorder.

Methods: For the cultural adaptation of the Portuguese version of the GAD-7 scale we started with a previous translation made by Mapi Institute and decided to perform a clinical review followed by a cognitive debriefing with patients. Once piloted, this version was then tested in a larger sample for feasibility and reliability (1-week test-retest). Construct validity was assessed by the relationship between GAD-7 and socio-demographic and clinical variables. Its unidimensionality was tested by principal component factor analysis. Criterion validity was assessed by comparing GAD-7 scores with those obtained by HADS, and EQ-5D. STAI was mainly used as a screening indicator for patient inclusion.

Results: GAD-7 was considered feasible with a mean completion time of 2.3 minutes and no major floor or ceiling effects. We found an excellent Cronbach's alpha internal consistency score (0.880) and the test-retest and interclass correlation coefficients were also very good. Regarding the construct validity, younger patients, those with higher education, employed and without anxiety symptoms revealed lower GAD-7 scores, meaning better health. The unidimensionality of GAD-7 index was also confirmed by principal component factor analysis. At last, GAD-7 was significantly correlated with other health outcome indices and the classification levels created by it and by HADS showed to be dependent.

Conclusion: The excellent metric properties confirmed the cultural adaptation and validity of GAD-7 into Portuguese population, allowing the clinicians an early detection and treatment of these patients.

References

    1. Andrews G, Hobbs MJ, Borkovec TD, Beesdo K, Craske MG, Heimberg RG, et al. Generalized worry disorder: a review of DSM-IV generalized anxiety disorder and options for DSM-V. Depress Anxiety. 2010;27(2):134–47. doi: 10.1002/da.20658.
    1. Behar E, DiMarco ID, Hekler EB, Mohlman J, Staples AM. Current theoretical models of generalized anxiety disorder (GAD): conceptual review and treatment implications. J Anxiety Disord. 2009;23(8):1011–23. doi: 10.1016/j.janxdis.2009.07.006.
    1. García-Campayo J, Zamorano E, Ruiz MA, Pardo A, Pérez-Páramo M, López-Gómez V, et al. Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool. Health Qual Life Outcomes. 2010;8:8. doi: 10.1186/1477-7525-8-8.
    1. Weisberg RB. Overview of generalized anxiety disorder: Epidemiology, presentation, and course. J Clin Psychiatry. 2009;70(2):4–9. doi: 10.4088/JCP.s.7002.01.
    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 3. Washington, DC: American Psychiatric Association; 1980.
    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 3. Washington, DC: American Psychiatric Association; 1987.
    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4. Washington, DC: American Psychiatric Association; 1994.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., Text Rev. Washington, DC. 2000.
    1. Sadock BJ, Sadock VA. Synopsis of Psychiatry, Behavioral Sciences/Clinical Psychiatry. 9. Philadelphia: Lippincott, Williams and Wilkins; 2003. p. 632.
    1. García-Campayo J, Zamorano E, Ruiz MA, Pérez-Páramo M, López-Gómez V, Rejas J. The assessment of generalized anxiety disorder: psychometric validation of the Spanish version of the self-administered GAD-2 scale in daily medical practice. Health Qual Life Outcomes. 2012;10:114. doi: 10.1186/1477-7525-10-114.
    1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602. doi: 10.1001/archpsyc.62.6.593.
    1. de Caldas Almeida JM, Xavier M. [National epidemiological study of mental health] Lisbon: Faculdade de Ciências Médicas, Universidade Nova de Lisboa; 2013.
    1. Hoge EA, Ivkovic A, Fricchione GL. Generalized anxiety disorder: diagnosis and treatment. BMJ. 2012;345:1–6. doi: 10.1136/bmj.e7500.
    1. Yonkers KA, Dyck IR, Warschaw M, Keller MB. Factors predicting the clinical course of generalized of anxiety disorder. Brit J Psychiat. 2000;176:544–9. doi: 10.1192/bjp.176.6.544.
    1. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63(Suppl 8):24–34.
    1. Bereza BG, Machado M, Einarson TR. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clin Ther. 2009;31(6):1279–308. doi: 10.1016/j.clinthera.2009.06.004.
    1. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25(1):72–90. doi: 10.1002/da.20257.
    1. Surtees PG, Wainwright NW, Khaw KT, Day NE. Functional health status, chronic medical conditions and disorders of mood. Br J Psychiatry. 2003;183:299–303. doi: 10.1192/bjp.183.4.299.
    1. Stein D. Comorbidity in generalized anxiety disorder: Impact and implications. J Clin Psychiatry. 2001;62(1):29–36.
    1. Telles-Correia D, Barbosa A. Anxiety and depression in medicine: models and measurement. Acta Med Port. 2009;22(1):89–98.
    1. Spitzer RL, Kroenke K, Williams JB, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Arch Intern Med. 2006;166(10):1092–7. doi: 10.1001/archinte.166.10.1092.
    1. Swinson RP. The GAD-7 scale was accurate for diagnosing generalised anxiety disorder. Evid Based Med. 2006;11(6):184. doi: 10.1136/ebm.11.6.184.
    1. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317–25. doi: 10.7326/0003-4819-146-5-200703060-00004.
    1. Acquadro C, Jambon B, Ellis D, Marquis P. Language and translation issues. In: Spilker B, editor. Quality of Life and Parmacoeconomics in Clinical Trrials. Philadelphia: Lippincott-Raven Publishers; 1996. pp. 575–85.
    1. Acquadro C, Conway K, Giroudet C, Mear I. Linguistic Validation Manual for Health Outcome Assessments. Lyon: Mapi Institute; 2012.
    1. De Vet HCW, Terwee CB, Mokkink LB, Knol DL. Measurement in Medicine. Cambridge: Cambridge University Press; 2011.
    1. Chronbach LJ. Coefficient alpha and the internal structure of tests. Phyc. 1951;16:297–334.
    1. Ferreira LN, Ferreira PL, Pereira LN, Oppe M. EQ-5D Portuguese population norms. Qual Life Res. 2014;23(2):425–30. doi: 10.1007/s11136-013-0488-4.
    1. Ferreira LN, Ferreira PL, Pereira LN, Oppe M. The valuation of the EQ-5D in Portugal. Qual Life Res. 2014;23(2):413–23. doi: 10.1007/s11136-013-0448-z.
    1. Ferreira PL, Ferreira LN, Pereira LN. How consistent are health utility values? Qual Life Res. 2008;17(7):1031–42. doi: 10.1007/s11136-008-9368-8.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Pais-Ribeiro J, Silva I, Ferreira T, Martins A, Meneses R, Baltar M. Validation study of a Portuguese version of the Hospital Anxiety and Depression Scale. Psychol Health Med. 2007;12(2):225–35. doi: 10.1080/13548500500524088.
    1. Spielberger CD, Gorssuch RL, Lushene PR, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, Inc; 1983.
    1. Lisboa JV, Augusto MG, Ferreira PL. Applied statistics to management. Porto: Vida Económica; 2012.
    1. Andlin-Sobocki P, Wittchen HU. Cost of affective disorders in Europe. Eur J Neurol. 2005;12(1):34–8. doi: 10.1111/j.1468-1331.2005.01195.x.
    1. Souêtre E, Lozet H, Cimarosti I, Martin P, Chignon JM, Adès J, et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res. 1994;38(Suppl 1):151–60. doi: 10.1016/0022-3999(94)90145-7.
    1. Candilis PJ, Pollack MH. The hidden costs of untreated anxiety disorders. Harv Rev Psychiatry. 1997;5:40–2. doi: 10.3109/10673229709034724.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit